Stock SANA SANA BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Sana Biotechnology, Inc.

Equities

SANA

US7995661045

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
9.08 USD +4.13% Intraday chart for Sana Biotechnology, Inc. +14.50% +122.55%
Apr. 18 Sana Biotechnology, Inc. Announces Resignation of Douglas Williams as Executive Vice President and President, Research and Development CI
Apr. 09 Certain Restricted Stock Units of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024. CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
AQ
Sana: Q4 Earnings Snapshot
AQ
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
GL
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
GL
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
GL
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
AQ
Breaking Ground in BioPharma: Spotlight Companies DYAI, INBS, SANA, IOVA, BLUE
AQ
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GL
Sana Biotechnology Announces Pricing of Upsized Public Offering
GL
Sana Biotechnology Announces Proposed Public Offering of Common Stock
GL
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
GL
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
GL
Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
GL
Sana Biotechnology to Present at November and December 2023 Investor Conferences
GL
Sana Biotechnology to Present at November and December 2023 Investor Conferences
AQ
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
PR
Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
GL
Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SANA Stock
  4. News Sana Biotechnology, Inc.
  5. Press Releases